Key facts: SELLAS Surges 233%, Drops 12%; SLS009 Data Expected Q4 2026

SELLAS (SLS) stock surged 233% on trial news, hitting a 52-week high with 57.6M shares traded. It later fell 12% after a $150M share sale. The company expects Phase 2 data for SLS009 in Q4 2026, according to Coinpedia.

Original reporting
Published Nov 18, 2026, 8:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 18, 2026, 8:13 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Key facts: SELLAS Surges 233%, Drops 12%; SLS009 Data Expected Q4 2026 — source image
Decision brief

The 30-second read

$SLSNeutralMed
01

Why it matters

The combination of trial optimism and a sizable equity raise creates a volatile trading environment.

02

Market read

The news drives short‑term price action in SLS and may influence sentiment toward similar biotech stocks.

03

What to watch

Potential regulatory scrutiny of the REGAL trial and dilution impact on existing shareholders.

Relevance 8/10Novelty 8/10Timing: today

Background

SELLAS Life Sciences Group announced preliminary topline data from its Phase 2 CDK9 inhibitor SLS009 are expected in Q4 2026, prompting a massive price swing.

Company-level read

Ticker impact

$SLSNeutralHigh confidence
Context

SELLAS (SLS) surged 233% on REGAL trial news and fell 12% after a $150 million share sale.

Expected impact

upside pressure from trial news tempered by downside from share dilution

Evidence & confidence

A 233% intraday move indicates strong buying interest, yet a $150 M equity raise typically depresses price.

Market effects

Positive signal for biotech trials may lift peer biotech stocks.

Limited to US biotech market.

Modest; primarily affects niche biotech investors.

Counterpoint

The share sale could trigger a sell‑off that outweighs the trial hype.

Key entities

  • SELLAS Life Sciences Group, Inc.

    Biotech firm developing CDK9 inhibitor SLS009.

Related articles

$NVDAMedAI 8/10

Futures Rise As Huang-less Nvidia Beats And Raises, Gold Crashes Below $3,800

US futures rise as Nvidia (NVDA) reports strong earnings and raises guidance, boosting AI-related stocks. Gold drops below $3,800 after Fed Governor Waller's comments. Nvidia's Q4 revenue guidance is $130B vs. estimates of $125B. Premarket movers include TSLA, GOOGL, AMZN, AAPL, META, AVGO, CRWV, AAOI, BLSH, DLB, LOW, SLS, TTWO, TNDM. Fed policy and economic data releases are in focus.

$SLSHighAI 9/10

SLS Joins MRNA And ANL In Biotech’s Top 3 This Year — Here’s How A Late-2025 Bet Could Grow 10x From Here

Sellas Life Sciences (SLS) reported positive Phase 3 trial results for its cancer vaccine, Galinpepimut-S (GPS), showing a 24-month median survival vs. 14.7 months in the control group. The company plans to meet with the FDA and aims to file for approval in early 2027. SLS also announced a $150M share offering to fund further development. Analysts and investors reacted positively, with some noting potential for expedited approval and broader applications.

$SLSHighAI 9/10

SLS Joins MRNA And ANL In Biotech’s Top 3 Winners This Year — Can Sellas Deliver Another Double From Here?

Sellas Life Sciences (SLS) stock surged 156% to $19.15 after positive Phase 3 trial results for its leukemia vaccine, Galinpepimut-S. The trial showed a 41% reduction in death risk, with median survival of 24 months vs. 14.7 months in the control group. Maxim Group raised its price target to $40, citing significant upside potential. SLS is planning a $150M share offering to fund further development.

$SLSMedAI 8/10

SELLAS shares jump 157% after company says its leukemia

SELLAS Life Sciences (SLS) shares surged 157% after reporting positive Phase 3 trial results for its leukemia vaccine, galinpepimut-S, showing a 41% reduction in death risk. The stock closed at $19.17, valuing the company at $3.9B. However, after launching a $150M stock offering, shares dropped 10-13% in after-hours trading. The trial enrolled 126 patients, with median survival of 24.0 months vs. 14.7 months for existing treatments. The company plans to file for regulatory approval in 2027.